

# Financial Tear Sheet

## Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187®, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the Settlement and License Agreement and received from Biogen a non-refundable cash fee of \$1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the EP2801355 Opposition Proceeding, including any appeal thereto.

## Stock Performance

### FWP (Common Stock)

<b>Exchange</b>	NASDAQ GS (US Dollar)
<b>Financial Status Indicator</b>	C
<b>Price</b>	<b>\$1.28</b>
<b>Change (%)</b>	▼ 0.1 (7.25%)
<b>Volume</b>	19,707
<b>52 Week Low</b>	\$0.71
<b>Rolling EPS</b>	-0.28
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	94,700,000



Data as of 02/19/19 4:00 p.m. ET

## Recent Headlines

10/24/18

Forward Pharma Provides Update on the Decision of the Federal Circuit in its Appeal of the U.S. Patent Interference

09/28/18

Forward Pharma to Participate in the Ladenburg Thalmann 2018 Healthcare Conference

09/19/18

Forward Pharma Reports Financial and Operational Results from the First Six Months of 2018

## Upcoming Events

<b>Date</b>	<b>Title</b>
04/10/19 through 04/11/19	<b>Forward Pharma A/S at DKBIO2019</b>

---

## SEC Filings

<b>Filing Date</b>	<b>Form</b>
02/14/19	SC 13G/A
01/15/19	6-K
11/26/18	6-K
10/24/18	6-K

## Corporate Governance

Claus Bo Svendsen, MD, PhD CEO

*Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources*